<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04612764</url>
  </required_header>
  <id_info>
    <org_study_id>5120</org_study_id>
    <nct_id>NCT04612764</nct_id>
  </id_info>
  <brief_title>Liver Disease in Urea Cycle Disorders</brief_title>
  <official_title>Noninvasive Biomarkers of Hepatic Fibrosis in Urea Cycle Disorders</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Baylor College of Medicine</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Children's National Research Institute</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Seattle Children's Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Children's Hospital Colorado</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Children's Hospital of Philadelphia</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Baylor College of Medicine</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a multi-center, cross-sectional study to assess risk for liver fibrosis and hepatic&#xD;
      injury in individuals with urea cycle disorders (UCDs) using serum biomarkers, Fibroscan, and&#xD;
      MRE. This study will be conducted at 5 sites of the Urea Cycle Disorders Consortium: Baylor&#xD;
      College of Medicine in Houston, TX, Seattle Children's Hospital in Seattle, WA, Children's&#xD;
      Hospital Colorado in Aurora, CO, Children's Hospital of Philadelphia in Philadelphia, PA, and&#xD;
      Children's National Medical Center in Washington D.C.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Urea cycle disorders (UCDs) are among the most common inborn errors of liver metabolism. With&#xD;
      early diagnosis and improved treatments, the survival of individuals with UCDs has improved,&#xD;
      and this improved survival has led to unmasking of some long-term complications such as&#xD;
      hepatic dysfunction and progressive fibrosis in a subset of patients. Hepatic complications&#xD;
      in UCDs are quite variable and dependent upon the specific metabolic defect.&#xD;
&#xD;
      Currently, there are no guidelines for monitoring hepatic complications or extent of liver&#xD;
      disease in UCDs. The gold standard for staging of fibrosis or confirming cirrhosis has&#xD;
      traditionally been liver biopsy, an invasive procedure with inherent risks, particularly in&#xD;
      the setting of a UCD and compromised coagulation. Recently, non-invasive serum and&#xD;
      imaging-based biomarkers have been introduced to assess hepatic fibrosis in adults and&#xD;
      children who are at increased risk. Utilization of these technique in individuals with UCDs&#xD;
      could be invaluable in both the research and clinical arenas.&#xD;
&#xD;
      The purpose of this study is:&#xD;
&#xD;
      1) To assess risk for increased fibrosis using serum biomarkers and/or VCTE in distal&#xD;
      disorders (ASS1D, ASLD and ARG1D) as compared to OTCD 2 ) To assess risk for hepatic fibrosis&#xD;
      (liver stiffness as measured by MRE) in individuals with UCDs who have abnormal serum&#xD;
      biomarkers and/or VCTE as those who have normal values&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">September 1, 2021</start_date>
  <completion_date type="Anticipated">December 31, 2023</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2023</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Other</observational_model>
    <time_perspective>Cross-Sectional</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Fibrotest</measure>
    <time_frame>One measurement made on the 1 day of the study visit (stage A)</time_frame>
    <description>Fibrotest(TM)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Fibroscan (liver stiffness)</measure>
    <time_frame>One measurement made on the 1 day of the study visit (stage A)</time_frame>
    <description>Liver stiffness (kPa) as assessed by Fibroscan®</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Fibroscan (CAP)</measure>
    <time_frame>One measurement made on the 1 day of the study visit (stage A)</time_frame>
    <description>Controlled Attenuation Parameter (CAPTM in dB/m) as assessed by Fibroscan®</description>
  </primary_outcome>
  <primary_outcome>
    <measure>MRE</measure>
    <time_frame>One measurement made on the 1 day of the study visit (stage B)</time_frame>
    <description>Liver stiffness (kPa) as measured by MRE</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Albumin</measure>
    <time_frame>One measurement made on the 1 day of the study visit (stage A)</time_frame>
    <description>Albumin</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Liver Enzymes</measure>
    <time_frame>One measurement made on the 1 day of the study visit (Stage A)</time_frame>
    <description>Aspartate aminotransferase, Alanine aminotransaminase, and Gamma glutamyl transferase</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total Bilirubin</measure>
    <time_frame>One measurement made on the 1 day of the study visit (stage A)</time_frame>
    <description>Total Bilirubin</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Prothrombin time</measure>
    <time_frame>One measurement made on the 1 day of the study visit (stage A)</time_frame>
    <description>Prothrombin time</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>INR</measure>
    <time_frame>One measurement made on the 1 day of the study visit (stage A)</time_frame>
    <description>INR</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AST-to-Platelet Ratio (APRI)</measure>
    <time_frame>One measurement made on the 1 day of the study visit (stage A)</time_frame>
    <description>AST-to-Platelet Ratio (APRI)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>GGT-to-Platelet Ratio (GPR)</measure>
    <time_frame>One measurement made on the 1 day of the study visit (stage A)</time_frame>
    <description>GGT-to-Platelet Ratio (GPR)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fibrosis-4 (FIB-4) Index</measure>
    <time_frame>One measurement made on the 1 day of the study visit (stage A)</time_frame>
    <description>Fibrosis-4 (FIB-4) Index</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>MRE</measure>
    <time_frame>One measurement made on the 1 day of the study visit (stage B)</time_frame>
    <description>Fat fraction (%) as measured by MRE</description>
  </secondary_outcome>
  <enrollment type="Anticipated">62</enrollment>
  <condition>Urea Cycle Disorder</condition>
  <condition>Ornithine Transcarbamylase Deficiency</condition>
  <condition>Citrullinemia 1</condition>
  <condition>ARGI Deficiency</condition>
  <condition>ASL Deficiency</condition>
  <condition>Argininosuccinic Aciduria</condition>
  <condition>ASS Deficiency</condition>
  <condition>Hyperargininemia</condition>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Blood&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Individuals with urea cycle disorders&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Stage A&#xD;
&#xD;
        Inclusion Criteria:&#xD;
&#xD;
          -  Age &gt; 6 years and &lt; 65 years&#xD;
&#xD;
          -  Weight ≥ 11 kg at time of screening&#xD;
&#xD;
          -  A molecular or biochemical diagnosis of OTCD, ASS1D, ASLD, or ARG1D.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Prior liver transplantation&#xD;
&#xD;
          -  Episode of acute hyperammonemia (≥100 umol/L) in the 30 days prior to enrollment&#xD;
&#xD;
          -  Confirmed diagnosis of chronic viral hepatitis, autoimmune liver disease, short gut,&#xD;
             small bowel syndrome, alcohol liver disease, TPN requirement, or TPN-related&#xD;
             cholestatic disease&#xD;
&#xD;
          -  Adults with BMI ≥ 45 kg/m2&#xD;
&#xD;
          -  Current pregnancy&#xD;
&#xD;
          -  Open wound near expected Fibroscan® probe application site&#xD;
&#xD;
          -  Use of implantable active medical device such as cardiac pacemaker or implantable&#xD;
             cardioverter-defibrillator&#xD;
&#xD;
        Stage B Inclusion Criteria&#xD;
&#xD;
        • Participation in Stage A of this study&#xD;
&#xD;
        Exclusion Criteria&#xD;
&#xD;
          -  Individuals with claustrophobia or other inability to complete&#xD;
&#xD;
          -  Known diagnosis of hemochromatosis&#xD;
&#xD;
          -  Presence of implants or devices incompatible with MRI&#xD;
&#xD;
          -  Inability to breath-hold for 20 seconds for the elastography sequence&#xD;
&#xD;
          -  Current pregnancy&#xD;
&#xD;
          -  Confirmed diagnosis of chronic viral hepatitis, autoimmune liver disease, short gut,&#xD;
             small bowel syndrome, alcohol liver disease, TPN requirement, or TPN-related&#xD;
             cholestatic disease&#xD;
&#xD;
          -  Episode of documented acute hyperammonemia (ammonia ≥ 100 umol/L) in the 30 days prior&#xD;
             to scheduled visit for Stage B&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>6 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Lindsay Burrage, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Baylor College of Medicine</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Saima Ali, MSN</last_name>
    <phone>832-822-4183</phone>
    <email>saima.ali@bcm.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>Children's Hospital Colorado</name>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <zip>80045</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>Brittany Murphy</last_name>
      <phone>720-777-8591</phone>
      <email>Brittany.Murphy@childrenscolorado.org</email>
    </contact>
    <investigator>
      <last_name>Shawn McCandless, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Children's National Medical Center</name>
      <address>
        <city>Washington</city>
        <state>District of Columbia</state>
        <zip>20010</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>Kara Simpson, MS, CGC</last_name>
      <phone>202-476-6216</phone>
      <email>ksimpson@childrensnational.org</email>
    </contact>
    <investigator>
      <last_name>Nicholas A Mew, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The Children's Hospital of Philadelphia</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>Bianca Ferreira, MPH</last_name>
      <phone>267-426-1368</phone>
      <email>ferreirab@email.chop.edu</email>
    </contact>
    <investigator>
      <last_name>Can Ficicioglu, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Seattle Children's Hospital</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98105</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>Linnea Brody, CRA</last_name>
      <phone>206-987-3012</phone>
      <email>Linnea.brody@seattlechildrens.org</email>
    </contact>
    <investigator>
      <last_name>Christina Lam, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>October 22, 2020</study_first_submitted>
  <study_first_submitted_qc>October 27, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">November 3, 2020</study_first_posted>
  <last_update_submitted>July 20, 2021</last_update_submitted>
  <last_update_submitted_qc>July 20, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 21, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Baylor College of Medicine</investigator_affiliation>
    <investigator_full_name>Lindsay Burrage</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>Liver disease</keyword>
  <keyword>Fibroscan</keyword>
  <keyword>Magnetic resonance elastography</keyword>
  <keyword>Fibrotest</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Urea Cycle Disorders, Inborn</mesh_term>
    <mesh_term>Ornithine Carbamoyltransferase Deficiency Disease</mesh_term>
    <mesh_term>Citrullinemia</mesh_term>
    <mesh_term>Argininosuccinic Aciduria</mesh_term>
    <mesh_term>Hyperargininemia</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

